Nitric oxide synthase gene therapy - MaxCyte/Northern Therapeutics

Drug Profile

Nitric oxide synthase gene therapy - MaxCyte/Northern Therapeutics

Alternative Names: eNOS transfected EPCs - Northern Therapeutics; Pulmonary hypertension gene therapy - MaxCyte/United Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MaxCyte; Northern Therapeutics
  • Class Gene therapies
  • Mechanism of Action Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension in Canada (Intrapulmonary)
  • 19 Dec 2016 Northern Therapeutics and Ottawa Hospital Research Institute plan the phase II SAPPHIRE trial for Pulmonary arterial hypertension (Adjunctive treatment) in Canada (IV) (NCT03001414)
  • 30 Mar 2011 Phase-I development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top